Meeting
2023 ASCO Annual Meeting
The role of volume of disease for treatment selection in patients with metastatic castration sensitive prostate cancer (mCSPC): A living meta-analysis.
Authors
Syed Arsalan Ahmed Naqvi
Mayo Clinic, Phoenix, AZ
Syed Arsalan Ahmed Naqvi , Irbaz Bin Riaz , Huan He , Manal Imran , Jacob Orme , Daniel S Childs , Praful Ravi , Syed A. Hussain , Parminder Singh , Alan Haruo Bryce
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Hormone-Sensitive
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5088)
DOI
10.1200/JCO.2023.41.16_suppl.5088
Abstract #
5088
Poster Bd #
182
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Comparative effectiveness of systemic treatments for metastatic castration-sensitive prostate cancer: A parametric survival network meta-analysis of randomized controlled trials.
First Author: Lin Wang
Poster
2023 ASCO Genitourinary Cancers Symposium
Deep prostate-specific antigen response and overall survival in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis.
First Author: Syed Arsalan Ahmed Naqvi
Poster
2022 ASCO Annual Meeting
Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs): A meta-analysis.
First Author: Deniz Can Guven
Poster
2022 ASCO Annual Meeting
Indirect comparisons of triplet therapy as compared to novel hormonal therapy doublets in patients with metastatic castration sensitive prostate cancer.
First Author: Syed Arsalan Ahmed Naqvi